Mirum Pharmaceuticals, Inc. (MIRM) Q4 FY25 Earnings Call

Strong commercial momentum is paired with four near-term readouts, but materially higher R&D spending delays expected positive cash flow.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-26
Length30 minutes
EPS$-0.11
Revenue$133.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q2 FY25

All MIRM earnings · Back to MIRM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.